Myovant Sciences Ltd (MYOV) Fundamental Analysis & Valuation

NYSE:MYOV • BMG637AM1024

Current stock price

26.98 USD
-0.01 (-0.04%)
At close:
26.98 USD
0 (0%)
After Hours:

This MYOV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MYOV Profitability Analysis

1.1 Basic Checks

  • In the past year MYOV has reported negative net income.
  • In the past year MYOV has reported a negative cash flow from operations.
MYOV Yearly Net Income VS EBIT VS OCF VS FCFMYOV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M

1.2 Ratios

  • MYOV has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MYOV Yearly ROA, ROE, ROICMYOV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K

1.3 Margins

  • Looking at the Gross Margin, with a value of 73.03%, MYOV belongs to the top of the industry, outperforming 84.43% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for MYOV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MYOV Yearly Profit, Operating, Gross MarginsMYOV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. MYOV Health Analysis

2.1 Basic Checks

  • MYOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MYOV has more shares outstanding
  • Compared to 1 year ago, MYOV has a worse debt to assets ratio.
MYOV Yearly Shares OutstandingMYOV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
MYOV Yearly Total Debt VS Total AssetsMYOV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

  • MYOV has an Altman-Z score of -2.98. This is a bad value and indicates that MYOV is not financially healthy and even has some risk of bankruptcy.
  • MYOV has a Altman-Z score of -2.98. This is in the lower half of the industry: MYOV underperforms 60.53% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.98
ROIC/WACCN/A
WACC7.64%
MYOV Yearly LT Debt VS Equity VS FCFMYOV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M -400M

2.3 Liquidity

  • A Current Ratio of 1.57 indicates that MYOV should not have too much problems paying its short term obligations.
  • MYOV has a Current ratio of 1.57. This is amonst the worse of the industry: MYOV underperforms 84.43% of its industry peers.
  • A Quick Ratio of 1.45 indicates that MYOV should not have too much problems paying its short term obligations.
  • The Quick ratio of MYOV (1.45) is worse than 83.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.45
MYOV Yearly Current Assets VS Current LiabilitesMYOV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. MYOV Growth Analysis

3.1 Past

  • MYOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.67%, which is quite impressive.
  • The Revenue has grown by 91.46% in the past year. This is a very strong growth!
EPS 1Y (TTM)22.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.24%
Revenue 1Y (TTM)91.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%84.11%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.08% on average over the next years. This is a very strong growth
  • MYOV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.18% yearly.
EPS Next Y19.42%
EPS Next 2Y25.59%
EPS Next 3Y20.67%
EPS Next 5Y25.08%
Revenue Next Year81.1%
Revenue Next 2Y53.4%
Revenue Next 3Y43.72%
Revenue Next 5Y45.18%

3.3 Evolution

MYOV Yearly Revenue VS EstimatesMYOV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B
MYOV Yearly EPS VS EstimatesMYOV Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. MYOV Valuation Analysis

4.1 Price/Earnings Ratio

  • MYOV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MYOV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MYOV Price Earnings VS Forward Price EarningsMYOV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYOV Per share dataMYOV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MYOV's earnings are expected to grow with 20.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.59%
EPS Next 3Y20.67%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MYOV Dividend Analysis

5.1 Amount

  • MYOV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MYOV Fundamentals: All Metrics, Ratios and Statistics

Myovant Sciences Ltd

NYSE:MYOV (3/9/2023, 8:04:00 PM)

After market: 26.98 0 (0%)

26.98

-0.01 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-26
Earnings (Next)05-08
Inst Owners0%
Inst Owner Change0%
Ins Owners55.37%
Ins Owner Change0%
Market Cap2.62B
Revenue(TTM)379.11M
Net Income(TTM)-183.77M
Analysts76
Price Target27.54 (2.08%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.15%
Min EPS beat(2)-21.77%
Max EPS beat(2)5.48%
EPS beat(4)2
Avg EPS beat(4)1.97%
Min EPS beat(4)-21.77%
Max EPS beat(4)32.17%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.97%
Min Revenue beat(2)-4%
Max Revenue beat(2)9.95%
Revenue beat(4)2
Avg Revenue beat(4)4.58%
Min Revenue beat(4)-12.72%
Max Revenue beat(4)25.09%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)1.22%
EPS NY rev (3m)1.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)1.22%
Revenue NY rev (3m)1.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.92
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.91
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-2.78
FCFYN/A
OCF(TTM)-2.78
OCFYN/A
SpS3.9
BVpS-5.74
TBVpS-5.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.03%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 65.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.45
Altman-Z -2.98
F-Score1
WACC7.64%
ROIC/WACCN/A
Cap/Depr(3y)67.93%
Cap/Depr(5y)160.76%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.24%
EPS Next Y19.42%
EPS Next 2Y25.59%
EPS Next 3Y20.67%
EPS Next 5Y25.08%
Revenue 1Y (TTM)91.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%84.11%
Revenue Next Year81.1%
Revenue Next 2Y53.4%
Revenue Next 3Y43.72%
Revenue Next 5Y45.18%
EBIT growth 1Y30.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.53%
EBIT Next 3Y15.08%
EBIT Next 5Y36.76%
FCF growth 1Y-161.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-160.74%
OCF growth 3YN/A
OCF growth 5YN/A

Myovant Sciences Ltd / MYOV Fundamental Analysis FAQ

What is the fundamental rating for MYOV stock?

ChartMill assigns a fundamental rating of 2 / 10 to MYOV.


What is the valuation status for MYOV stock?

ChartMill assigns a valuation rating of 0 / 10 to Myovant Sciences Ltd (MYOV). This can be considered as Overvalued.


How profitable is Myovant Sciences Ltd (MYOV) stock?

Myovant Sciences Ltd (MYOV) has a profitability rating of 0 / 10.


How financially healthy is Myovant Sciences Ltd?

The financial health rating of Myovant Sciences Ltd (MYOV) is 1 / 10.


What is the earnings growth outlook for Myovant Sciences Ltd?

The Earnings per Share (EPS) of Myovant Sciences Ltd (MYOV) is expected to grow by 19.42% in the next year.